Novel Targets, Treatments Needed for Melanomas Not Responding to Targeted Immunotherapies

Source: Cancer Therapy Advisor, June 2018

Advancements in targeted therapies and immunotherapy have transformed the landscape of treatment for metastatic melanoma. Recent data show that as many as 70% of patients with metastatic melanoma survive for one year with the use of these novel therapies, with about half of patients achieving a long-term benefit.